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MaOBJECTIVES The aim of this study was to determine if a baseline high-sensitivity troponin T (hsTnT) value #99th
percentile upper reference limit (0.014 mg/l [“low hsTnT”]) identiﬁes patients at low risk for adverse outcomes.
BACKGROUND Approximately 85% of patients who present to emergency departments with acute heart failure are
admitted. Identiﬁcation of patients at low risk might decrease unnecessary admissions.
METHODS A post-hoc analysis was conducted from the RELAX-AHF (Serelaxin, Recombinant Human Relaxin-2, for Treat-
mentofAcuteHeart Failure) trial,which randomizedpatientswithin 16hofpresentationwhohad systolic bloodpressure>125
mm Hg, mild to moderate renal impairment, and N-terminal pro–brain natriuretic peptide$1,600 ng/l to serelaxin versus
placebo. Linear regression models for continuous endpoints and Cox models for time-to-event endpoints were used.
RESULTS Of the 1,076 patients with available baseline hsTnT values, 107 (9.9%) had low hsTnT. No cardiovascular (CV)
deaths through day 180 were observed in the low-hsTnT group compared with 79 CV deaths (7.3%) in patients with
higher hsTnT. By univariate analyses, low hsTnT was associated with lower risk for all 5 primary outcomes: 1) days alive
and out of the hospital by day 60; 2) CV death or rehospitalization for heart failure or renal failure by day 60; 3) length of
stay; 4) worsening heart failure through day 5; and 5) CV death through day 180. After multivariate adjustment, only
180-day CV mortality remained signiﬁcant (hazard ratio: 0.0; 95% conﬁdence interval: 0.0 to 0.736; p ¼ 0.0234;
C-index ¼ 0.838 [95% conﬁdence interval: 0.798 to 0.878]).
CONCLUSIONS No CV deaths through day 180 were observed in patients with hsTnT levels#0.014 mg/l despite high
N-terminal pro–brain natriuretic peptide levels. LowbaselinehsTnTmay identify patientswith acute heart failure at very low
risk for CV mortality. (J Am Coll Cardiol HF 2016;4:591–9) © 2016 by the American College of Cardiology Foundation.T he primary goal of hospital-based risk strati-ﬁcation in acute heart failure (AHF) is theidentiﬁcation of patients at highest risk for
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
AHF = acute heart failure
CI = conﬁdence interval
CV = cardiovascular
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593with AHF are admitted, the costliest resource in
health care is already overconsumed: hospitalization
(5). Identifying patients safe for discharge is the un-
met need of ED AHF risk stratiﬁcation (6). With
nearly 800,000 annual AHF admissions originating
from EDs, safe discharge, or observation status, for
even a small fraction of patients would yield tremen-
dous health care cost savings (7).SEE PAGE 600
ED = emergency department
HF = heart failure
hsTnT = high-sensitivity
troponin T
NT-proBNP = N-terminal pro–
brain natriuretic peptide
RF = renal failureUnfortunately, no prospectively validated, facile,
accepted AHF risk instruments for use in the ED
setting exist (8–12). Risk scores derived from admin-
istrative data show promise, but their lack of external
prospective validation or difﬁculty of use has limited
their uptake (13–16). Even the creation of risk in-
struments in the ED setting is difﬁcult. Because most
patients are admitted, separating the inﬂuence of
hospitalization on the prognostic trajectory of pa-
tients is difﬁcult (12). This limits the applicability of
hospital-based AHF risk scores to the ED setting.
Emergency physicians’ low tolerance of risk com-
pounds the problem: survey work suggests that sig-
niﬁcant adverse events cannot exceed 1% (17). Thus,
identiﬁcation of low-risk patients with AHF in the ED
setting is a major unmet clinical need.
Myocardial injury, as measured by troponin
release, is a marker of higher risk (18–21). A previous
RELAX-AHF (Serelaxin, Recombinant Human
Relaxin-2, for Treatment of Acute Heart Failure)
analysis demonstrated that baseline, peak, and peak
change in high-sensitivity troponin T (hsTnT) was
associated with worse outcomes (22). Similar to acute
coronary syndrome (ACS), higher levels of troponin
are associated with worse outcomes in AHF
(18–20,23). Unlike ACS, the potential value of nega-
tive troponin values in AHF is less well known. The
value of troponin may be greater in discriminating
low from high risk.
The increasing sensitivity of troponin assays had
led to increased detection of myocardial injury in
AHF: 6.2% in ADHERE (Acute Decompensated Heart
Failure National Registry; published in 2008),
approximately 50% in the ASCEND-HF (Acute Study
of Clinical Effectiveness of Nesiritide in Decom-
pensated Heart Failure) trial (published in 2011), and
more than 90% in the RELAX-AHF trial (published in
2013). Although trials enroll higher risk patients at
baseline compared with registries, the trend is infor-
mative. Perhaps myocardial injury is a key patho-
physiologic marker in the majority of patients with
AHF; prior to higher sensitivity assays, it was more
difﬁcult to detect (21). Thus, we tested whether the
absence of myocardial injury identiﬁes a subgroup ofpatients with signs and symptoms of AHF at
very low risk for adverse events.
METHODS
OBJECTIVE. The objective of this study was
to determine the association between a low
baseline hsTnT level (#99th percentile upper
reference limit) and outcomes.
STUDY DESIGN. The design, rationale, and
results of the RELAX-AHF trial have been
previously reported (19,24,25). Brieﬂy, this
was an international, multicenter, random-
ized, placebo-controlled trial of serelaxin
versus placebo, infused over 48 h, both in
addition to usual care. To be included, patients had to
have signs and symptoms of heart failure (HF), radio-
graphic evidence of pulmonary congestion, systolic
blood pressure >125 mm Hg, brain natriuretic peptide
or N-terminal pro–brain natriuretic peptide (NT-
proBNP) >350 ng/ml or >1,400 ng/ml, respectively,
mild to moderate renal dysfunction, treatment with
intravenous loop diuretic agents, and randomization
within 16 h of presentation. All clinical trial sites were
Institutional Review Board or ethics committee
approved to participate in RELAX-AHF. The trial was
registered at ClinicalTrials.gov (NCT00520806).
OUTCOMES AND STATISTICAL ANALYSIS. Pre-spec-
iﬁed endpoints from the RELAX-AHF trial were used.
These included days alive and out of the hospital
through day 60, cardiovascular (CV) death or HF or
renal failure (RF) hospitalization through day 60,
length of initial hospital stay, worsening HF through
day 5, and CV mortality through day 180. Mode of
death and rehospitalization were adjudicated by an
independent, blinded committee. Because this was an
exploratory study, additional analyses were per-
formed for the following outcomes: 180-day all-cause
mortality; worsening HF by day 14; dyspnea visual
analogue scale area under the curve through day 5;
marked or moderate improvement in dyspnea by
Likert-type scale at 6, 12, and 24 h; and CV death or
HF or RF hospitalization through 30 days. Of these,
180-day all-cause mortality was a pre-speciﬁed safety
endpoint in the main trial. Both dyspnea endpoints
were the original coprimary efﬁcacy outcomes, and
worsening HF was a pre-speciﬁed exploratory efﬁcacy
endpoint. Only CV death or HF or RF hospitalization
by 30 days was a new endpoint constructed for this
analysis. Correction for multiple comparison testing
was not performed.
Patients were divided into 2 groups on the basis of
baseline hsTnT #0.014 mg/l. Patient characteristics
are presented as frequencies and percentages for
TABLE 1 Baseline Ch
Percentile Upper Refe
Demographics and hea
failure characte
Age, (yrs)
Male
White/Caucasian
Left ventricular EF (%
EF <40%
Ischemic heart diseas
Time from presentat
to randomizati
NYHA functional clas
before admissi
I
II
III
IV
Clinical signs
Systolic blood pressu
Diastolic blood press
Heart rate (beats/mi
HF hospitalization in
Serelaxin administrat
Congestion at baseline
Edema
Orthopnea
JVP
Dyspnea on exertion
Rales
Comorbidities
Hypertension
Hyperlipidemia
Diabetes mellitus
Stroke or other
cerebrovascula
Asthma, bronchitis, o
History of atrial
ﬁbrillation or ﬂ
History of CRT or ICD
procedures
Myocardial infarction
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594categorical variables, mean  SD, or geometric mean
(95% conﬁdence interval [CI]) if log transformed, as
appropriate. Comparisons between groups were done
using chi-square or Fisher exact tests as indicated or
Student t tests or Wilcoxon rank sum tests if not
normally distributed.
Results from both univariate and multivariate
analyses are presented, using predictor variables of
clinical importance and consistent with past RELAX-
AHF analyses (24,26). See Online Table 1 for a list of
the covariates, which included, among other variables,
age, sex, blood pressure, treatment, NT-proBNP,
creatinine, and blood urea nitrogen. Online Table 1aracteristics by Baseline Troponin Above or Below the 99th
rence Limit of 0.014 mg/l
Elevated Troponin
(n ¼ 969)
Low Troponin
(n ¼ 107) p Value*
rt
ristics
72.5  10.7 71.0  11.1 0.1560
623 (64.3) 42 (39.3) <0.0001
926 (95.6) 101 (94.4) 0.6219 [F]
) 38.4  14.5 42.8  13.8 0.0036
509 (55.9) 41 (40.6) 0.0033
e 516 (53.3) 47 (43.9) 0.0668
ion
on (h)
8.0  4.7 7.0  4.4 0.0286
s 30 days
on
280 (29.2) 27 (25.2) 0.0609
237 (24.7) 39 (36.4)
322 (33.6) 32 (29.9)
120 (12.5) 9 (8.4)
re (mm Hg) 142.4  16.5 141.7  15.4 0.6813
ure (mm Hg) 78.7  14.1 80.8  14.2 0.1406
n) 79.2  14.7 82.2  15.3 0.0477
past year 327 (33.7) 29 (27.1) 0.1658
ion 477 (49.2) 58 (54.2) 0.3283
762 (78.7) 88 (82.2) 0.3952
929 (96.0) 99 (92.5) 0.1278 [F]
714 (75.5) 76 (72.4) 0.4862
954 (99.6) 106 (100.0) 1.0000 [F]
923 (95.3) 99 (92.5) 0.2197
836 (86.3) 94 (87.9) 0.6515
521 (53.8) 53 (49.5) 0.4048
493 (50.9) 30 (28.0) <0.0001
r event
134 (13.8) 11 (10.3) 0.3077
r COPD 158 (16.3) 10 (9.3) 0.0598
utter
496 (51.2) 64 (59.8) 0.0901
253 (26.1) 21 (19.6) 0.1441
342 (35.3) 29 (27.1) 0.0907
Continued on the next pagepresents the adjustment variables included in the
multivariate models. Of note, NT-proBNP was
modeled as a continuous variable. Linear regression
models were created for noncategorical endpoints,
and Cox models for time-to-event endpoints. (Pro-
portional hazards assumptions were checked and
satisﬁed.) These models are conservative, as all clin-
ical variables of interest were included. However,
given the concern for overspeciﬁcation, additional
models with greater efﬁciency were created using
backward elimination (Online Table 3). Cross validated
C-indexes were calculated to allowmodel comparison.
Statistical signiﬁcance was set at the 0.05 level.
When no events were observed in a patient subgroup
of interest, score test methods were used to report p
values and CIs. In all other cases, Wald procedures
were used.
BIOMARKERS. Plasma hsTnT (Roche Elecsys Assay;
Roche Diagnostics GmbH, Mannheim, Germany) was
measured, per protocol, at baseline (a median of 8.7 h
after initial presentation). The 99th percentile upper
reference limit was 0.014 mg/l, and the lowest con-
centration with a coefﬁcient of variation #10% was
0.013 mg/l. Patients with low hsTnT levels were deﬁned
by values #0.014 mg/l (14 ng/l). All samples were
analyzed in a central laboratory in a blinded manner.
RESULTS
BASELINE CHARACTERISTICS. Of the 1,161 patients
enrolled in the RELAX-AHF trial, 1,076 had hsTnT
measured at baseline. Of these, 107 (9.9%) did not
have evidence of myocardial injury (baseline value
#0.014 mg/l). Table 1 shows baseline characteristics
stratiﬁed by hsTnT #0.014 mg/l. Age was similar
between the groups, with an average age of 71 years in
the low-hsTnT group. Fewer patients in the low-hsTnT
group were male or had reduced ejection fractions.
There were no differences in baseline vital signs, with
the exception of heart rate being 3 beats/min faster
in the low-hsTnT group. Of note, there were no dif-
ferences in history of ischemic heart disease, New York
Heart Association class, HF hospitalization in the
past year, or signs and symptoms of HF. With the
exception of oral loop diuretic agents and beta-
blockers, there were no other differences in terms of
baseline medications. Fewer patients had histories of
diabetes, but no other signiﬁcant differences in
comorbidities were observed. In terms of laboratory
values, low-hsTnT patients had better renal function
and lower NT-proBNP levels (median 3,422 vs. 5,313
ng/l in the elevated-hsTnT group) (Online Table 2
lists a comprehensive comparison of baseline
characteristics).
TABLE 1 Continued
Elevated Troponin
(n ¼ 969)
Low Troponin
(n ¼ 107) p Value*
Baseline laboratory values†
Sodium (mmol/l) 140.81  3.65 140.94  3.18 0.7179
Hemoglobin (g/dl) 12.76  1.85 12.97  1.88 0.2869
Potassium (mmol/l) 4.28  0.64 4.25  0.63 0.6296
Creatinine (mmol/l) 118.7  33.5 98.1  25.7 <0.0001 [S]
Uric acid (mmol/l) 480.8  136.7 425.0  120.0 <0.0001
BUN (mmol/l) 10.01  4.11 8.00  2.73 <0.0001 [S]
Cystatin C (mg/l) 1.48 (1.46–1.51) 1.23 (1.18–1.29) <0.0001 [S]
NT-proBNP (ng/l) 5,313 (5,029–5,613) 3,422 (2,893–4,047) <0.0001
eGFR (ml/min/1.73 m2) 52.78  12.85 58.39  12.91 <0.0001
Total cholesterol (mmol/l) 4.09  1.18 4.10  1.08 0.9789
Glucose (mmol/l) 7.85  3.72 7.09  2.67 0.0090 [S]
Devices
Pacemaker 106 (10.9) 7 (6.5) 0.1592
Implantable cardiac
deﬁbrillator
131 (13.5) 12 (11.2) 0.5052
Biventricular pacing 98 (10.1) 7 (6.5) 0.2374
Medication
(day 0, except nitrates)
ACE inhibitors 526 (54.3) 65 (60.7) 0.2022
ACE inhibitors or ARBs 659 (68.0) 78 (72.9) 0.3016
ARBs 158 (16.3) 17 (15.9) 0.9115
Beta-blockers 648 (66.9) 86 (80.4) 0.0044
Aldosterone antagonists 317 (32.7) 28 (26.2) 0.1686
Oral loop diuretic agents
30 days prior
46.5 (67.3) 34.0 (57.5) 0.0373 [S]
Digoxin 200 (20.6) 14 (13.1) 0.0632
Nitrates at randomization 74 (7.6) 4 (3.7) 0.1400
Values are mean  SD or geometric mean (95% conﬁdence interval) if log transformed, presented for continuous
variables, and n (%) for categorical variables (percentage based on total number of patients with nonmissing
values for the endpoint). *For continuous variables, p values are based on Student t tests. For categorical
variables, p values are based on chi-square tests if the count in each cell is >1 and the count is $5 for at least
80% of the cells. Otherwise, Fisher exact test was used. “[F]” indicates that the Fisher exact test was used to
calculate the p value. “[S]” indicates that the Satterthwaite method was used to calculate the p value because of
unequal variance in comparison groups. †The following variable was log transformed: NT-proBNP.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BUN ¼ blood urea nitrogen;
COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; EF ¼ ejection fraction;
eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; ICD ¼ implantable cardioverter-deﬁbrillator;
JVP ¼ jugular venous pressure; NT-proBNP ¼ N-terminal pro–brain natriuretic peptide; NYHA ¼ New York
Heart Association.
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595Table 2 presents the 5 primary outcomes by uni-
variate and multivariate analyses, including troponin
level by treatment interaction. Covariates used for
the multivariate model are listed in Online Table 1. By
univariate analysis, low hsTnT (#99% upper refer-
ence limit) was signiﬁcantly associated with more
favorable outcomes for all 5 primary outcomes.
However, by multivariate analysis, only CV mortality
at day 180 remained signiﬁcant: no patients with low
hsTnT experienced CV death through 180 days (haz-
ard ratio: 0.0; 95% CI: 0.0 to 0.736; p ¼ 0.0234; C-
index ¼ 0.838 [95% CI: 0.798 to 0.878]). Of the 85
patients without baseline hsTnT values, 9 died of CV
causes through day 180. Of the 969 patients with
elevated hsTnT, 79 died of CV causes through day
180. Given the potential concern for overﬁtting the
model, Online Table 3 shows the results of a more
efﬁcient backward elimination multivariate model,
demonstrating similar signiﬁcance for 180-day CV
mortality (hazard ratio: 0.0; 95% CI: 0.0 to 0.737;
p ¼ 0.0225; C-index ¼ 0.812 [95% CI: 0.770 to 0.855]).
Table 3 shows the association between hsTnT sta-
tus and the 6 secondary outcomes by univariate
analysis only. With the exception of dyspnea
improvement by Likert-type scale and CV death or HF
or RF rehospitalization by day 30, the 4 remaining
outcomes demonstrated statistically signiﬁcant as-
sociations with lower risk.
Given the absence of 180-day CV events in the
low-hsTnT group, a multivariate analysis of 180-
day all-cause mortality was performed and did not
show statistical signiﬁcance (p ¼ 0.0788) (Online
Table 3). Only 1 patient with low hsTnT died of a
non-CV cause.
DISCUSSION
In this post hoc analysis of the RELAX-AHF trial, pa-
tients with baseline hsTnT values below the 99th
percentile (low hsTnT) were at signiﬁcantly lower risk
for CV death through day 180. In fact, there were no CV
deaths in this group. Importantly, patients with low
hsTnTweremore likely to be female and to have higher
ejection fractions. However, there were more similar-
ities than differences between the groups. Further-
more, low hsTnT remained signiﬁcant after
adjustment for known markers of risk, such as
NT-proBNP, renal function, serum sodium, blood
pressure, hemoglobin, and baseline historical features
andmedications. This suggests that patientswith signs
and symptoms of AHF,without evidence ofmyocardial
injury as measured by hsTnT assay, are at very low risk
for CV death. Given that only 1 non-CV death occurred,
hsTnT may be a powerful marker of low risk.Past studies have demonstrated that lower values
of troponin are associated with lower risk (22). How-
ever, it is not clear what threshold value of troponin
deﬁnes low risk, speciﬁcally, to inform early decision
making. Unique to this analysis is the potential value
of the absence of hsTnT in patients with AHF, spe-
ciﬁcally, hsTnT #99th percentile of the reference
upper limit. Further strengths of this analysis include
the use of a contemporary high-sensitivity assay,
central laboratory processing, independent adjudi-
cation of events, and the largest published cohort
of hsTnT from a contemporary AHF trial. In a previ-
ous analysis of the RELAX-AHF dataset, the lowest
quartile of hsTnT was associated with lower risk
for CV outcomes (22). However, this group included
patients above and below the 99th percentile;
TABLE 2 Effect (95% Conﬁdence Interval) of Low Versus Elevated Troponin at Baseline in Univariate and Multivariate Models for Primary Outcomes and p Values
for Models Including Treatment by Troponin Interactions
Outcome
Elevated Troponi‡‡
(n ¼ 969)
Low Troponin‡‡
(n ¼ 107)
Univariate Model*
(n ¼ 1,076)
Multivariate Model†
(n ¼ 1,076)
Multivariate Model
With Interaction‡
(n ¼ 1,076)
Effect p Value Effect p Value
Interaction
p Value
Days alive and out of
hospital by day 60§
47.71 (46.95 to 48.47) 51.38 (50.32 to 52.44) 3.67 (1.36 to 5.98) 0.0018 1.88 (0.44 to 4.19) 0.1128 0.1758
CV death or rehospitalization
for HF or renal failure
by day 60||
132 (13.62%) 7 (6.54%) 0.46 (0.22 to 0.99) 0.0472 0.76 (0.34 to 1.71) 0.5053 0.6751
Length of initial hospital
stay§
10.24 (9.64 to 10.84) 7.81 (7.09 to 8.54) 2.43 (4.23 to 0.62) 0.0085 1.54 (3.35 to 0.26) 0.0944 0.2129
Worsening heart failure
by day 5||
100 (10.32%) 3 (2.80%) 0.26 (0.08 to 0.82) 0.0217 0.30 (0.09 to 1.03) 0.0566 0.2102**
CV death through day 180|| 79 (8.15%) 0 (0.00%) 0 (0 to 0.42¶) 0.0025 0 (0 to 0.74¶#) 0.0234 —††
Values are hazard ratio (95% conﬁdence interval). *Independent variable is dichotomized (low vs. elevated) troponin. †Adjustment variables are as listed in Online Table 1 and treatment. ‡Troponin level by
treatment interaction term is added to multivariate model. §Continuous endpoint: mean difference (95% CI) reported as effect. ||Time-to-event endpoint: HR (95% CI) reported as effect. ¶There were no
cardiovascular death events in the low-troponin group. This caused the Wald chi-square test to be unreliable, so much so that SAS could not produce an upper conﬁdence limit. Upper conﬁdence limits and p
values were produced using score-test methods instead. #No patient scored 0 on BMDEX (BMDEX ¼ baseline dyspnea on exertion-imputed) at level 0 had a CVDT180 event (CVDT 180 ¼ CV death through
day 180). BMDEX ¼ 0 and BMDEX ¼ 1 are grouped together as the reference level. **Interaction p value was calculated using the score-test chi-square statistic with 1 degree of freedom. ††There was
insufﬁcient information in the data to estimate the interaction p value. ‡‡Mean (95% CI) is presented for continuous outcomes, and n (%) is presented for time-to-event outcomes.
CV ¼ cardiovascular; HF ¼ heart failure.
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596thus, the threshold value of hsTnT to deﬁne low
risk is unknown. A less sensitive assay was used in
ASCEND-HF (27). Unlike the RELAX-AHF trial,
patients were enrolled up to 24 h after presentation.
Furthermore, only 50% of patients had troponin
values above the 99th percentile. In ASCEND-HF, an
elevated troponin value at baseline was not associ-
ated with 30- or 180-day post-discharge outcomes.
Although elevated troponin did predict length of
hospital stay and in-hospital worsening HF, the
prognostic value of troponin values below the 99th
percentile were not reported (27).
By itself, focusing on the absence of a marker of
injury in CV disease is not novel; it is a common
approach in ACS and remains an area of active study,TABLE 3 Effect (95% Conﬁdence Interval) of Low Versus Elevated Tr
Outcome
Elevated Troponin||
(n ¼ 969)
All-cause mortality by day 180‡ 92 (9.49%)
WHF by day 14‡ 141 (14.55%)
Total dose of IV loop diuretic
agents through day 5†
189.50 (169.35 to 209.66)
Dyspnea VAS AUC to day 5† 2,502.39 (2,318.63 to 2,686.15)
Moderate or marked
improvement by Likert-type
scale at 6, 12, 24 h§
263 (27.14%)
CV death or rehospitalization
for HF or renal failure by day 30‡
72 (7.43%)
Values are hazard ratio (95% conﬁdence interval). *Independent variable is dichotomized
as effect. ‡Time-to-event endpoint: HR (95% CI) reported as effect. §Categorical endp
outcome, and n (%) is presented for binary and time-to-event outcomes.
AUC ¼ area under the curve; IV ¼ intravenous; OR ¼ odds ratio; VAS ¼ visual analogdespite decades of work to identify lower risk patients
with chest pain. In ACS, lower values of troponin are
associated with better outcomes. Identifying the
threshold value for low risk remains an active area of
study (28). Similar to ACS, future AHF work involving
hsTnT assays will require careful scrutiny of patient
selection, serial testing, and peak values. Unlike ACS,
biomarker research to identify patients with signs and
symptoms of HF who are at low risk in the ED setting is
in its infancy. Well-established AHF risk scores for use
in the ED setting are lacking, though several show
promise (13). Although observation unit pathways
exist, they are underused and lack the supportive
evidence from a robust randomized controlled trial
(11). In fact, American Heart Association and Americanoponin at Baseline in Univariate Models for Secondary Outcomes
Low Troponin||
(n ¼ 107)
Univariate Model*
(n ¼ 1,076)
Effect p Value
1 (0.93%) 0.09 (0.01 to 0.68) 0.0187
7 (6.54%) 0.42 (0.2 to 0.91) 0.0275
122.29 (85.71 to 158.87) 67.21 (129.11 to 5.32) 0.0333
3,270.76 (2,814.25 to 3,727.27) 768.37 (196.53 to 1,340.21) 0.0084
28 (26.17%) 0.95 (0.6 to 1.5) 0.8313
4 (3.74%) 0.491 (0.18 to 1.34) 0.1659
(low vs. elevated) troponin. †Continuous endpoint: mean difference (95% CI) reported
oint: OR (95% CI) reported as effect. ||Mean (95% CI) is presented for continuous
ue scale; WHF ¼ worsening heart failure; other abbreviations as in Table 2.
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597College of Cardiology HF guidelines focus on man-
agement once hospitalized, highlighting the paucity
of ED-based evidence (29).
In the setting of low-risk identiﬁcation, these ﬁnd-
ings from a clinical trial support its potential role in the
real-world setting. Clinical trials generally enroll
higher risk patients. For example, if patients with low
hsTnT values did not have AHF at all—despite amedian
NT-proBNP level >3,400 pg/ml, signs and symptoms,
admission for AHF, and inclusion in a clinical trial
the value of low hsTnT in an ED population of pa-
tients with signs and symptoms of HF still holds.
Patients may only appear to be higher risk at the
time of presentation. Another hypothesis is that
cardiac injury may deﬁne AHF. With increasingly
sensitive troponin assays, patients without hsTnT
release may: 1) not have AHF; 2) have less severe
AHF; or 3) represent a unique phenotype. More than
90% of patients in RELAX-AHF had hsTnT release,
supporting this injury-deﬁning theory; however, it
remains a preliminary hypothesis.
This study, however, did not show adjusted dif-
ferences in rehospitalization. Whether preventing a
ﬁrst hospitalization leads to a return ED visit is not
well known. More important, whether safe preven-
tion of an initial admission alters outcomes for pa-
tients is also unknown. Factors that contribute
to early mortality, however, may differ from those
that contribute to rehospitalization (30). Non-CV
comorbidities play a key role, as well as socioeco-
nomic and psychosocial issues. Focusing solely on
myocardial injury or CV comorbidities will be insuf-
ﬁcient to dramatically improve outcomes. Although
hospitalization independently predicts a worse
outcome (31,32), whether the prevention of unnec-
essary hospitalization for patients with AHF worsens
the prognosis of patients, improves it, or makes no
difference requires further study. Regardless, any
successful discharge strategy must ensure symptom
alleviation as well as robust transitions of care. Given
that many hospitals already use transitional care
strategies for hospitalized patients, leveraging such
resources to the ED or observation unit setting would
facilitate uptake of a strategy of low risk to discharge
with close follow-up.
Future studies using hsTnT to stratify risk should
target lower risk ED patients with AHF. Current clin-
ical decision making already leads to admission for
most patients (33,34). Focusing on high risk is of
relatively less value in the ED setting. Identifying
even a small fraction of patients safe for discharge,
coupled with robust transitions of care, would result
in a signiﬁcant decrease in the absolute number ofhospitalized patients. Whether troponin release at
baseline reﬂects the severity of underlying structural
heart disease, decompensation, or both is not well
known. Serial values that demonstrate rising, falling,
or peak values would better inform the mechanisms
of myocardial injury in patients with AHF.
STUDY LIMITATIONS. A major limitation of this study
is the absence of patients discharged from the ED.
Risk stratiﬁcation schemata derived from already
hospitalized patients may not identify ED patients
safe for discharge (13–15,35,36). Multimarker ap-
proaches were also not considered because a recent
study demonstrated the potential value of such an
approach in hospitalized patients (36). However, we
did adjust for known prognostic markers, and in the
ED setting, troponins are routinely ordered as part of
clinical care. Importantly, the results are hypothesis
generating only. Another major limitation is the small
number of patients with low hsTnT (n ¼ 107). How-
ever, the RELAX-AHF trial enrolled a higher risk
group of patients with AHF compared with real-world
patients. A larger proportion of patients may actually
have low hsTnT. Whether these ﬁndings apply to
patients who do not meet the trial inclusion and
exclusion criteria was not examined. There is the
possibility that not all patients had AHF, as it remains
a clinical diagnosis without an established gold
standard. Although the strict inclusion and exclusion
criteria suggest that this is unlikely, this would not
rule out the potential value of low hsTnT in patients
with AHF signs and symptoms; it may prompt the
search for alternative diagnoses. Other strategies to
leverage hsTnT in AHF were not tested: 1) different
thresholds of hsTnT, such as the limit of detection; 2)
more rapid serial testing (i.e., 0 and 3 h); and 3) as
part of a risk score.
CONCLUSIONS
In the RELAX-AHF trial, no patient with an hsTnT
value below the 99th percentile upper reference limit
died through 180 days. Future studies are needed to
conﬁrm whether absence of myocardial injury iden-
tiﬁes ED patients with AHF safe for discharge or brief
observation.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
absence of validated, facile risk instruments for EDs car-
ing for patients with AHF contributes to the very high
proportion of admissions. Troponin, as a marker of
myocardial injury in AHF, is a known prognostic marker.
However, it has been studied primarily as a marker of high
risk; whether absence of troponin release is associated
with low risk has not been previously well studied. In this
post hoc study, baseline hsTnT #99th percentile identi-
ﬁed patients at very low risk for 180-day CV mortality.
TRANSLATIONAL OUTLOOK: Because this was a post
hoc analysis, further work is needed to verify the poten-
tial clinical value of hsTnT in AHF patients in the ED
setting. In the United States however, studying dis-
charged patients with AHF is difﬁcult because most pa-
tients are admitted. Thus, separating the impact of
hospitalization from baseline risk is difﬁcult. Neverthe-
less, given the high proportion of admissions, this
hypothesis-generating study should lead to future work
exploring the role of hsTnT as a marker of low risk in
patients with AHF. We suggest studying hsTnT in patients
with lower risk features in the ED setting, as higher risk
patients will likely be admitted regardless.
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